Science 37 receives the 2026 BioTech Breakthrough Award for its innovative direct-to-patient clinical trial approach.
Science 37, based in Morrisville, North Carolina, has been awarded the title of "BioTechnology Innovation of the Year" at the recent 2026 BioTech Breakthrough Awards. This recognition highlights their groundbreaking Direct-to-Patient Site model, which has redefined how clinical trials engage with patients across the country.
Transforming Clinical Trial Accessibility
For many years, clinical trials have required participants to be within a certain proximity to physical research locations, thereby limiting who could take part. Science 37 is actively reshaping this framework by serving as a centralized research site with a national reach. Their innovative model allows pharmaceutical companies to broaden the participant pool without the overhead of establishing a physical site network.
Innovative Direct-to-Patient Approach
Utilizing expert medical oversight and having licensed investigators in all 50 states, Science 37 is able to deliver clinical research services directly to patients' homes through their specialized mobile nursing teams. This direct engagement not only complements traditional clinical trial sites but also offers an essential alternative that enhances enrollment rates and encourages patient participation throughout the duration of trials.
Measurable Success
A study conducted by the Tufts Center for the Study of Drug Development reveals notable benefits associated with Science 37's approach:
- Higher Participant Enrollment: On average, Science 37 has enrolled 150 participants in each trial, far exceeding the 26 participants typically engaged at conventional sites.
- Significant Contributions to Trials: As a singular research site, they are accountable for 20-30% of total enrollment across the trials analyzed.
- Improved Retention Rates: Science 37 exhibits completion rates that are over 50% greater than industry averages.
- Diverse Participant Pool: Their model has demonstrated an increased representation of women and Black participants, addressing disparities in clinical research.
To date, Science 37 has facilitated more than 200 clinical trials spanning Phases I to IV, including observational studies, and has completed over 14,000 in-home clinical evaluations. The company has also successfully passed five Phase 3 FDA inspections, achieving a No Action Indicated (NAI) status without receiving any Form 483 observations. This track record underscores their commitment to operating within strict regulatory standards.
“Science 37 is challenging one of the longstanding limitations of clinical research: the assumption that patients must travel to a physical site to participate,” stated Bryan Vaughn, Managing Director of BioTech Breakthrough.
As the complexity of clinical development continues to escalate, Science 37 is dedicated to advancing its direct-to-patient model across various therapeutic fields and research methodologies. Their goal reflects a pressing need for clinical research to be accessible to all, regardless of geographical constraints.
For more information, visit www.science37.com.
